NUOVA MODALITA’ PER IL REPORT DI META-ANALISI : “PRISMA STATEMENT ” 2020

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews Matthew J. Page et al. Abstract The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past…

IL BENEFICIO IN TERMINI DI SOPRAVVIVENZA E’ RIDOTTO AD ASSENTE PER I FARMACI ONCOLOGICI APPROVATI : L’ESPERIENZA CANADESE

Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada Daniel E. Meyers et al. IMPORTANCE Cancer drugs approved by the US Food and Drug Administration have come under scrutiny for marginal clinical benefits; however, the clinical benefits of cancer drugs recommended for reimbursement in Canada have not been adequately…

ABSOLUTE RISK O RELATIVE RISK ? PER SENSIBILIZZARE IL PUBBLICO SUI VACCINI E’ MEGLIO IL RISCHIO RELATIVO?

Relative risk rather than absolute risk reduction should be preferred to sensitise the public to preventive actions: letter   Nicolas Chapelle et al. We thank Lawrence and colleagues1 for their interest in our work,2 about which they raised some comments as the need of expressing results in absolute rather than relative risks. As they appropriately mentioned in…